The etiology of systemic lupus erythematosus (SLE) involves a complex interaction of genetic and environmental factors. Investigations have shown that environmentally driven epigenetic changes contribute to the etiology of SLE. Here, we hypothesize that aberrant DNA methylation may contribute to the activation of the immune machinery and trigger lupus disease activity. A whole genome methylation array was applied to investigate the DNA methylation changes between 12 pairs of active SLE patients and healthy controls. The results were further confirmed in 66 SLE patients, 102 healthy controls. The methylation statuses of the IL10 and IL1R2 genes were significantly reduced in the SLE patient samples relative to the healthy controls (age-adjusted odds ratios, 64.2 and 16.9, respectively, Po0.0001). There was a trend toward SLE patients having hypomethylated IL10 and IL1R2 genes accompanied by greater disease activity. We observed that the methylation degree of IL10 and IL1R2 genes were reduced in the rheumatoid arthritis (RA) patients as well but the hypomethylation change was more significant in IL1R2 genes than in the IL10 genes in RA patients. This study demonstrated that DNA hypomethylation might be associated with SLE. Hypomethylated IL10 and IL1R2 genes may provide potential epigenetic markers as clinical predictors for autoimmune diseases.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a rheumatic autoimmune disorder affecting mainly women of childbearing age. The abnormal immunological response is characterized by a loss of B-cell tolerance, an abnormal interaction between T-and B-cell signaling, B-cell hyperactivity and the production of autoantibodies. 1 The etiology of SLE has remained unknown, but viral infection, exposure to some drugs, hormonal factors and genetic mutation may partly account for SLE, even though no single factor contributes to SLE. 2 Research has indicated that SLE has familial clustering and a genetic link. Genes located in the HLA region, IRF5, PTPN22, STAT4, CDKN1A, ITGAM, BLK, TNFSF4, IFIH1, CFB, CLEC16A, IL12B, SH2B3 and BANK1 contain risk variants for SLE.
DNA methylation in the regulatory sequences of some genes is associated with transcriptional inactivation, whereas hypomethylation of these sequences is associated with active transcription. The abnormally regulated T-and B-cell activity and complex inheritance of SLE may be linked to aberrant DNA methylation. The first evidence of aberrant DNA methylation patterns in the development of SLE was that T cells from active SLE patients exhibited decreased deoxymethylcytosine content and reduced DNA methyltransferase activity. 7 Additional evidence of the role of methylation changes in the development of SLE comes from drug-induced SLE. People taking procainamide or hydrazaline may develop an autoimmune syndrome characterized by arthritis, serositis and antinuclear antibodies, which could be caused by autoreactive T cells. 8, 9 These drugs stimulate the demethylating activity by affecting the DNA methyltransferase activity. 10 Exposing T cells to demethylating drugs results in the demethylation-dependent induction of lupus-like disease. 11, 12 All of this accumulated evidence supports that DNA methylation changes may be critical in the clinical manifestation of SLE.
Identification of the genes that are dysregulated through DNA methylation changes in SLE contributes to our understanding of the pathway of the disease. However, the full repertoire of genes affected is not known. Since there is more and more evidence supporting the fact that epigenetic factors play some roles in the pathogenesis of SLE, we hypothesize that aberrant DNA methylation may contribute to the activation of the immune machinery and trigger lupus disease activity. Here, we investigated the epigenetic markers using a genome-wide analysis and identified the DNA hypomethylation changes associated with SLE disease activity.
RESULTS

Whole genome methylation analysis
A whole genome methylation analysis was performed on 12 patients with active SLE and 12 normal controls. The average betas (methylation degree) were 0.048 and 0.054 for the SLE group and the control group, respectively (P ¼ 0.0001) (Figure 1 ). The scatter plots comparing the average DNA methylation pattern illustrated 2165 genes with significant methylation changes between the two groups (Po0.01, Student's t-test) (Figure 2 ).
Ingenuity pathway analysis
To identify the pathways and functional groups enriched by differentially methylated loci, the 2165 genes were entered into the Ingenuity Pathway Analysis database and the Database for Annotation, Visualization and Integrated Discovery (Ingenuity Systems, Inc., Redwood City, CA). The top 250 genes with major difference methylation levels (average b) are listed in Supplementary Table 1 . The top physiological system development and function identified by the differentially methylated loci were involved in hematological system development and function, immune cell trafficking, organ morphology, reproductive system development and function, and embryonic development (Supplementary Table 2 ). We observed a significant network of cellular movement, hematological system development and function, and immune cell trafficking (Figure 3 ). The serum level of IL10 has been reported to be correlated with SLE disease activity and severity, while the high level of IL1R2 may reduce the effect of the IL1 cytokine. 13 --18 Therefore, we used these two candidates for further validation.
Methylation degree of IL10 and IL1R2 gene and its clinical correlation The target sites of these two genes were one CpG located 493 bp upstream of the transcriptional start site for IL10 (Probe cg17067005) and another at 114 bp upstream of the transcriptional start site (TSS) for IL1R2 (Probe cg17142183). The two CpGs were assayed using the bisulfite sequencing and single nucleotide primer extension (SNuPE) protocols. A positive correlation was found between the methylation degrees of the IL10 and IL1R2 genes by SNuPE and the average beta methylation values from the whole genome methylation array.
To gather further evidence from a wider selection of samples, we used SNuPE to examine the methylation degree of 66 SLE patients and 102 healthy controls, and the results were confirmed by bisulfite sequencing (Supplementary Figure 1) . We observed a remarkable decrease in the DNA methylation levels of the SLE subjects as compared to the healthy controls for the IL10 and IL1R2 genes (Figure 4 , for the IL10 gene, the mean methylation degree of the SLE group and the control group ¼ 0.272 and 0.428, Po0.0001; for the IL1R2 gene, 0.043 and 0.103, Po0.0001, respectively). Twelve patients with rheumatoid arthritis (RA) were also included as disease controls (the mean methylation degree of the IL10 and IL1R2 genes ¼ 0.375 and 0.023, respectively). We observed the methylation degree of IL10 and IL1R2 genes were reduced in the RA patients as well but the hypomethylation change was more significant in IL1R2 genes than in the IL10 genes in RA patients (Supplementary Figure 2) . One of the third RA patients had hypomethylated IL10 genes while all of the twelve RA patients had hypomethylated IL1R2 genes. People with hypomethylation of the IL10 or IL1R2 gene were prone to developing SLE (Table 1 , age-adjusted odds ratios, 64.2 and 16.9, respectively). Hypomethylation of one allele of either the IL10 or IL1R2 genes indicated an increased risk for SLE, while hypomethylation of both alleles resulted in an even higher risk for SLE (ageadjusted ORs, 3.8 and 101.8, respectively).
We next compared the serum cytokine levels of the 66 SLE patients with those of the 102 healthy controls using the enzymelinked immunosorbent assay. Figure 5 demonstrates that the mean serum protein concentration of IL10 was significantly higher in the SLE patients than in the controls, but that of IL1R2 was not (P ¼ 0.000 and 0.292, respectively). However, the mean serum protein concentration of IL10 of the RA patients was not significantly different from that of the SLE patients or the healthy control. But the mean serum protein concentration of IL1R2 of the RA patients was significantly higher than that of SLE patients or the healthy controls. Moreover, we found the DNA methylation degrees of both the Il10 and IL1R2 genes were inversely correlated with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score in the SLE patients ( Figure 6 , P ¼ 0.047 and 0.037, respectively). The patients with greater severity had less methylated promoter of the IL10 and IL1R2 genes. In the patients with SLE, there was a trend toward increasing frequency of hypomethylation with the disease severity ( Figure 7 ). About 60, 70 and over 90% of the patients, respectively, had mild SLE, moderate SLE and severe SLE, and had hypomethylated IL10 and IL1R2 genes, while less than 20% of the controls had the two genes hypomethylated. With the accumulated evidence of epigenetic factors in the development of SLE, we applied the whole genome methylation array to investigate the DNA methylation pattern in SLE.
In this context, our study found global hypomethylation in SLE patients and identified a potential epigenetic network of immune machinery using Ingenuity Pathway Analysis. We further found that the methylation statuses of the IL10 and IL1R2 genes were significantly reduced in the SLE patient samples relative to those of the healthy controls. There was a trend toward having hypomethylated IL10 and IL1R2 genes in the SLE patients with greater disease severity. In other words, people with hypomethylated IL10 and IL1R2 genes may be prone to having SLE or having higher activity levels of SLE.
An imbalance between Th-1 and Th-2 cytokine production plays a key role in the induction and development of SLE. 19, 20 In particular, a switch from a type I to a type II T-helper has been demonstrated, where the serum levels of the Th-2 cytokines such as interleukin IL-4, IL-6 and IL-10 are elevated, while there is an observed decrease in the production of Th-1 cytokines including IL-1, IL-2 and interferon IFN-g. 1, 21, 22 Among these cytokines, IL-10 seems to play a central role in the pathogenesis of SLE as well as in disease flare induction. 1 IL-10 is an important immunoregulatory cytokine that inhibits T-cell function, inhibits antigen-presenting cells and promotes B-cell-mediated functions. Therefore, the IL10 gene has been extensively investigated and situated in a major SLE susceptibility locus (1q31-32). 23 However, we reached no conclusive result about its involvement in SLE susceptibility. 24 One meta-analysis study showed only an association of the IL10.G11 allele with SLE susceptibility in the populations analyzed (odds ratio ¼ 1.279; 95% confidence interval: 1.027 --1.593; P ¼ 0.028). 25 We instead noted the inverse relationship existing between DNA methylation and SLE disease activity and the high association between the hypomethylated IL10 genes and SLE (odds ratio ¼ 22.061; 95% confidence interval: 9.643 --50.473; P ¼ 0.000). The dysregulated IL10 concentration may come from the DNA methylation regulation, not the DNA sequence variants.
On the other hand, IL-1R2 binds IL-1A and IL-1B with high affinity, and the IL-1 antagonist, IL-1RA, with lower affinity. IL-1R2 may act as a decoy receptor, interfering with the binding of IL-1 to IL-1R1. 18 Our findings were compatible with this theory. The reduced effect of the Th-1 cytokine, IL1, may result from the DNA hypomethylation of the IL1R2 gene, which leads to more IL1R2 receptors and interferes with the IL1 function in the SLE patients.
Javierre et al. 26 also identified that changes in the pattern of DNA methylation were associated with twin discordance in SLE using a whole genome methylation array (GoldenGate Methylation Cancer Panel I, Illumina, Inc., San Diego, CA, USA). They identified 49 genes with differential methylation between the SLE-affected and the healthy monozygotic twin pairs, including Figure 3 . The detected 2165 genes were input into the Ingenuity Pathway Analysis, which determined the network of cellular movement, hematological system development and function, and immune cell trafficking.
the IL10 gene. They further confirmed their findings of eight genes using bisulfite pyrosequencing, but the IL10 gene was not included. In our study, we detected 2165 genes with differential methylation between the SLE patients and the controls. The IL10 gene was hypomethylated and identified in our study as well.
Although we used samples from 12 active SLE patients instead of discordant twins, we further confirmed our findings using a larger number of case --control pairs and found the incidence of hypomethylation increased with the SLE disease activity. The results of both studies showed the different DNA methylation pattern in the SLE patients, especially in the IL10 gene. This further affirmed our result.
We had 12 RA patients as disease controls, and hypomethylated IL10 and IL1R2 genes presented in the RA patients as well. However, the hypomethylated IL10 gene was noted in 33.3% (4 out of 12) of the RA patients and in 72.7% of the SLE patients, whereas the hypomethylated IL1R2 gene was noted in 100% (12 of 12) of the RA patients and 66.7% of the SLE patients. The serum level of IL1R2 protein of the RA patients was significantly higher than that of the SLE patients or the healthy controls, which was not observed in the serum level of IL10 protein. T-cell hypomethylation and reduced DNA methyltransferase activity were reported in both the active SLE patients and the RA patients. 7 We demonstrated that the affected patterns might be different in the two autoimmune disorders, which may result from the different pathogenesis, mechanism or disease entities. Due to the limited number of RA cases in this study, further investigation is warranted.
The advantage of the epigenetic marker is the stability of DNA, although cytokines are easily degraded under preservation. This may also explain the low correlation of the methylation degree and the cytokine concentration of the IL10 and IL1R2 genes. The reported IL10 serum concentrations of the SLE patients vary greatly: 0 --7.6 pg ml À1 in Mellor-Pita's report 27 and 250 --2000 pg ml À1 in al-Janadi's report. 28 Accordingly, there was a positive correlation between IL10 production and the SLEDAI score in the SLE patients, 27 ,29,30 but Llorente et al. 13 failed to detect such a correlation. The discordance may be attributed to the easily degraded characteristics of cytokines, making the epigenetic marker a better choice for clinical use.
Our findings identified potentially relevant DNA methylation markers for the clinical characterization of SLE patients and supported the notion that epigenetic changes may be critical in the clinical manifestation of SLE. However, the study had some limitations. First, the studied material was DNA from white blood cells. We did not answer the question of what specific immune cells were hypomethylated. Zhao et al. 31 have shown that abnormal hypomethylation is a determinant of IL10 expression in CD4 þ T cells. Llorente et al. 13 also reported that the IL10 concentrations were higher in monocytes than in T or B cells. As we can detect the methylation changes from the DNA of non-sorted white blood cells, sorted specific immune cells may have a greater difference in their degree of methylation. As we would like to use these epigenetic markers as clinical predictors, it would be easier to extract DNA from peripheral white blood cells than to sort cells, which may require a larger amount of peripheral blood from the patients. Second, each SLE patient may receive different immunosuppressant therapies. We did not control for this factor in the regression model. The major medical treatments of the SLE patients in this study were prednisone, hydroxycholoquine, cyclophosphamide and azathioprine. Most patients took at least two of these medicines. The reasons why the IL10 and IL1R2 genes were hypomethylated remain unclear. It has been suggested that some transcriptional factors may be involved in regulating the methylation status of methylation-sensitive genes in lupus T cells. 31 Whether the hypomethylated genes noted in the SLE patients are the initiators of the disease or the responders to some other etiologies needs to be answered. Further follow-up of the people with no SLE but with hypomethylated IL10 or IL1R2 genes may help to clarify the question. Also, the serial data of the methylation status in SLE patients with disease flares and remissions are critical to understanding the relationship of the regulatory element and SLE disease activity. The IPA analysis of the 2165 differentially methylated genes reveals a significant enrichment in networks that are potentially relevant in autoimmune inflammatory disease, such as immune cell trafficking, and hematological system development and function. Work-up of the genes in the network such as IL6R, STAT5A, IFN type I and GFI 1 may further illuminate the disease mechanism.
In summary, hypomethylation of IL10 and IL1R2 might be related to the disease activity of SLE, and people with a hypomethylated allele of either the IL10 or IL1R2 gene may have a greatly increased risk for SLE. There is no currently identified means to predetermine the course of illness in any given individual. 32 Our findings provide potential clinical markers for susceptibility, disease flare-up and clinical courses in autoimmune diseases. Figure 5 . The bar plots show the mean protein concentration of IL10 and ILR2 in the SLE patients, RA patients and control groups. The IL10 concentration was statistically significantly higher in the SLE patient group, but not the IL1R2 concentration (Po0.0001 and P ¼ 0.292, respectively). The RA patients had significant higher IL1R2 protein concentration than SLE or controls. However, the IL10 level of RA patients was not significantly different from that of SLE or controls. When the severity increases, the chance of DNA hypomethylation increases as well. Table 3) . 33 The SLE patients were classified into three groups according to their response to medical treatment and current disease status. There were 22 cases with active SLE, 15 with stable SLE and 29 with inactive SLE. In all, 12 RA patients were included as disease controls (Supplementary Table 4) . A volume of 6 ml of peripheral blood was collected from each enrolled sample: 3 ml for DNA extraction and 3 ml for serum preservation. Total DNA was isolated from white blood cells by standard procedures and stored at À20 1C.
MATERIALS AND METHODS Patients
Bisulfite treatment
The MethylCode Bisulfite Conversion Kit (Invitrogen, Carlsbad, CA, USA) was used to treat DNA (1 g) with bisulfite according to the manufacturer's instructions. The reaction causes the conversion of unmethylated cytosines to uracil without changing the status of the methylated cytosines, which can be detected by sequencing.
Whole genome methylation array Methylation scores represented as b-values were generated for each site using BeadStudio 3.2 software (Illumina), and were computed based on the ratio of methylated to methylated plus unmethylated signal outputs. Thus the b values ranged from 0 (unmethylated) to 1 (fully methylated) on a continuous scale. 34 The Illumina Infinium methylation assay was performed according to the manufacturer's instructions, and this assay along with its technical validation is detailed in Bibikova et al. 35 Bisulphite-converted DNA was denatured, amplified, fragmented and subsequently hybridized, with the use of a specific hybridization buffer, to the chip arrays (Sentrix positions A-L) (Illumina). Primer extension was performed, then stained and coated, followed by imaging with the Illumina BeadArray reader. Internal quality controls included assessment of staining, hybridization, target removal, extension, bisulfite conversion efficiency, dye specificity and additional negative controls.
Ingenuity pathway analysis
Ingenuity Pathway Analysis software 8.0. edition (Ingenuity Systems, http:// www.ingenuity.com) and the Database for Annotation, Visualization and Integrated Discovery were used to carry out network composition analyses. Canonical pathway analysis identified the pathways that were most significant to the data set from the Ingenuity Pathway Analysis library of canonical pathways. The significance of the association between a data set and the canonical pathway was measured in two ways: (1) a ratio of the number of molecules from the data set that map to the pathway divided by the total number of molecules that map to the canonical pathway was displayed; (2) Fisher's exact test was used to calculate a P-value determining the probability that the association between the genes in the dataset and the canonical pathway was explained by chance alone. 
SNuPE
The SNuPE assay was performed using the bisulfite-converted DNA with two different sets of primers specific for the methylated and unmethylated CpG sites. SNuPE were carried out in 10 ml containing 50 --60 ng of the template fragment (the purified PCR product), 1 Â SNPStart Master Mix, 1 mM interrogation primer (GenomeLab SNPStart primer 
Enzyme-linked immunosorbent assays
The protein concentrations in the serum from the SLE patients and healthy controls were measured using ELISA kits (R&D Systems, Minneapolis, MN, USA for IL1R2 and BD Biosciences, San Jose, CA, USA for IL10), following the protocols of the manufacturers. Optical density values were read at 450 nm using the EL Â 800 Absorbance Microplate Reader (BioTek, Winooski, VT, USA).
Statistical analysis
Student's t-test for equality of means was used to compare values. P-values of o0.05 were considered significant. The odds ratios of the different DNA methylation statuses were calculated by logistic regression. The group differences of the methylation degrees of the IL10 and IL1R2 genes were calculated by the analysis of variance test. The correlation of the SLEDAI score and the methylation degrees of IL10 and IL1R2 genes was calculated by Pearson's test. All analyses were performed with SPSS version 18.0 software (SPSS, Inc., Chicago, IL, USA).
